Beneficial effects of paricalcitol on cardiac dysfunction and remodelling in a model of established heart failure.

María TamayoLaura Martín-NunesAlmudena Val-BlascoMaria José G M-PiedrasJosé Alberto Navarro-GarcíaEduardo LagePatricia PrietoLuis M RuilopeMaría Fernández-VelascoCarmen Delgado

Published in: British journal of pharmacology (2020)

The results suggest that paricalcitol treatment in established HF hampers disease progression and improves adverse electrophysiological and Ca2+ handling remodelling, attenuating the vulnerability to HF-associated ventricular arrhythmias. Paricalcitol may emerge as a potential therapeutic option in the treatment of HF.

Keyphrases

heart failure
left ventricular
acute heart failure
emergency department
combination therapy
atrial fibrillation
adverse drug